The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes

• Status: Recruiting
• Trial end date: 2024-10-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to prove that the group treated with D745 in combination added that the reduction of HbA1c superior to placebo treated group added in combination.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chong Kun Dang Pharmaceutical

Criteria

Inclusion Criteria:

• between 19 years and 85 years old(male or female)

• Type 2 diabetes mellitus

• BMI between 18.5kg/m2 and 40kg/m2

• Agreement with written informed consent

Exclusion Criteria:

• Type 1 diabetes mellitus or secondary diabetes mellitus

• Patients with complications of severe diabetes such as proliferative diabetic retinopathy

• Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

• Patients with abnormal laboratory test results according to the protocol

• Continuous or non continuous treatment insulin within 12 weeks prior to screening

• Chronic oral or non oral corticosteroids treatment within 4 weeks prior to screening